Etoricoxib isn’t banned worldwide, but it was never approved in the United States, which is why many English-speaking readers assume it’s been pulled from the market. In 2005, an FDA advisory committee voted 20 to 1 against approving the drug because of concerns about cardiovascular safety. The medication is sold under the brand name Arcoxia in over 60 other countries, including throughout Europe, Asia, and Latin America, where regulators decided the benefits outweighed the risks with proper monitoring.
Why the FDA Rejected Etoricoxib
Etoricoxib is a COX-2 inhibitor, a type of anti-inflammatory painkiller designed to be gentler on the stomach than older drugs like ibuprofen or naproxen. It belongs to the same drug class as rofecoxib (Vioxx), which was pulled from the global market in 2004 after it was linked to heart attacks and strokes. That withdrawal made regulators everywhere far more cautious about approving new COX-2 inhibitors.
When Merck submitted its application for etoricoxib, the FDA’s own reviewer concluded that the clinical data showed a cardiovascular safety signal. This signal was present whether etoricoxib was compared to naproxen or to other traditional anti-inflammatory drugs. The timing mattered enormously: the Vioxx scandal was still fresh, and the bar for proving heart safety in this drug class had risen sharply. The near-unanimous 20-to-1 advisory committee vote effectively ended the drug’s path to the U.S. market.
What the Cardiovascular Data Actually Showed
The largest study on etoricoxib’s heart safety was the MEDAL program, published in The Lancet, which enrolled nearly 35,000 patients with osteoarthritis or rheumatoid arthritis. Researchers compared etoricoxib head-to-head with diclofenac, one of the most widely used anti-inflammatory drugs in the world. The results showed that 320 patients on etoricoxib and 323 patients on diclofenac experienced blood-clot-related cardiovascular events like heart attacks or strokes. The event rates were nearly identical: 1.24 per 100 patient-years for etoricoxib versus 1.30 for diclofenac.
In other words, etoricoxib didn’t appear more dangerous for the heart than a drug already on the market in every major country. But the FDA’s concern was broader than a single comparison. The agency wanted to see that etoricoxib was safe relative to naproxen, which some evidence suggests may actually protect the heart slightly. When measured against that benchmark, etoricoxib looked worse. The FDA ultimately decided the overall risk-benefit picture didn’t justify approval, particularly when existing painkillers were already available to American patients.
Why Other Countries Still Approve It
European regulators took a different approach. The European Medicines Agency reviewed the same cardiovascular data and concluded that etoricoxib could be prescribed safely with the right restrictions. Rather than rejecting the drug outright, they imposed strict conditions. Patients whose blood pressure is persistently above 140/90 mmHg and not adequately controlled cannot take it. Blood pressure must be checked and stabilized before starting treatment, monitored again two weeks after the first dose, and rechecked regularly for as long as someone stays on the medication.
These restrictions reflect a real concern: etoricoxib tends to raise blood pressure more than some other anti-inflammatory drugs. By screening out patients with poorly controlled hypertension and monitoring everyone else closely, European regulators believed they could keep the risk manageable. Countries across Asia, Latin America, and the Middle East followed a similar logic and approved the drug with comparable safeguards.
The Stomach Safety Advantage
The reason etoricoxib remains popular where it is approved comes down to its effect on the digestive system. COX-2 inhibitors were designed to reduce pain and inflammation without damaging the stomach lining the way older anti-inflammatory drugs do. The MEDAL study confirmed this: upper gastrointestinal events like bleeding, ulcers, and perforations were 31% less common in patients taking etoricoxib compared to those on diclofenac. For uncomplicated stomach problems specifically, the reduction was even larger at 43%.
This matters most for people who need daily anti-inflammatory medication for chronic conditions like arthritis. Traditional drugs like ibuprofen, naproxen, and diclofenac carry a well-known risk of stomach ulcers and bleeding, especially with long-term use. For patients who are at high risk of gastrointestinal complications but have healthy cardiovascular systems and normal blood pressure, etoricoxib can be a genuinely useful option. That trade-off, less stomach damage but careful heart monitoring, is one that many regulatory agencies outside the U.S. decided was worth making.
What This Means if You Can’t Get It
If you’re in the United States, etoricoxib is not available by prescription or over the counter, and there’s no indication the FDA plans to revisit the decision. Celecoxib is the only COX-2 inhibitor currently approved in the U.S. and fills a similar role for people who need stomach-friendly anti-inflammatory treatment. If you’ve been prescribed etoricoxib while traveling or living abroad and are now looking for it in the U.S., your doctor can help identify an alternative that fits your situation.
If you’re in a country where etoricoxib is available and you’re wondering whether it’s safe to take, the key factors are your cardiovascular history and your blood pressure. The drug works well for osteoarthritis (typically at 30 to 60 mg once daily), rheumatoid arthritis (90 mg), and short-term gout flares (120 mg). But those doses come with the expectation that your prescriber is checking your blood pressure regularly and that you don’t have uncontrolled heart disease or hypertension.